Trial Profile
A human POC study of CMIO-ONDAN
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 02 Apr 2020
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 06 Feb 2019 According to a ChemioCare media release, this study is expected to be conducted in mid-2019.
- 25 Oct 2018 New trial record
- 18 Oct 2018 According to a ChemioCare media release, the trial is expected to complete in mid 2019.